Occlusion Balloon vs. 5FR Ureteral Catheter
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jan 23, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a special device called an occlusion balloon catheter during a procedure known as percutaneous nephrolithotomy (PCNL), which is used to remove kidney stones. The goal is to see if using this balloon helps prevent tiny pieces of stones from moving into the ureter (the tube that carries urine from the kidney to the bladder) after the procedure. The researchers want to compare the results of patients who have PCNL with and without this balloon to understand if it makes a difference.
To participate in this trial, you need to be an adult aged 18 or older, have kidney stones, and be scheduled for the PCNL procedure. However, if you are pregnant or have certain urinary tract issues, you may not be eligible. If you join the study, you can expect to receive care as usual during your procedure, and the research team will monitor the outcomes to see how well the occlusion balloon works. This trial is currently looking for participants, so it could be a good opportunity to contribute to important research on kidney stone treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 years and older.
- • Diagnosed with kidney stones and scheduled for PCNL.
- • Able and willing to provide informed consent.
- Exclusion Criteria:
- • Pregnant women
- • Urinary tract anomalies such as urinary diversion, previous ureteral reconstruction surgeries, horseshoe kidney, solitary kidney, duplicated system, urinary stricture disease, ureteropelvic junction obstruction, pelvic kidney, stone in calyceal diverticulum.
- • Prone procedure
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Mantu Gupta, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported